BETHESDA, Md. - Marylandian -- Dr. Zaher Nahle, Founder and CEO of Ivyctory Solutions and Senior Scientific Advisor at the Center for a Humane Economy, completed a series of engagements in Boston, including an invited special talk at InnoPharm 2026 and a meeting with the chief editor of Drug Discovery Online.

Nahle delivered his special talk at InnoPharm 2026, the 2nd International Conference on Innovations in Pharma R&D, held November 2–4. His presentation examined biomedical research modernization, the evolving regulatory landscape, and the growing role of human-relevant technologies in pharmaceutical development. The conference took place amid significant federal initiatives to reduce reliance on animal testing and accelerate the evaluation and adoption of New Approach Methodologies (NAMs).

A central focus of Nahle's scientific and policy work is reassessing longstanding regulatory assumptions, particularly where conventional preclinical methods have demonstrated limited predictive value for human outcomes. His analyses call for stronger evidentiary standards, rigorous evaluation of emerging technologies, and regulatory decisions grounded in measurable scientific performance rather than historical precedent.

More on Marylandian

• Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
• OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
• Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
• The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
• Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration

Beyond his scientific and technical publications, Nahle regularly authors analyses examining institutional barriers to biomedical modernization, scientific and regulatory challenges surrounding NAMs, and their implications for pharmaceutical development and investment decisions. Notable works include Path Dependency and the Rescuing of the Biomedical Research Enterprise (Frontiers in Medical Technology) and Wall Street Is Wary of NAMs—and for Good Reason (Drug Discovery Online).

During the visit, Nahle met with Ray Dogum, chief editor of Drug Discovery Online, where he serves on the Editorial Advisory Board. The meeting included discussions of current developments in pharmaceutical research and the publication's programming for 2027.

Nahle was also invited to attend an operations management class at his alma mater, Harvard Kennedy School, providing an opportunity to exchange ideas and share professional developments since graduation.

The Boston engagements underscore Ivyctory Solutions' commitement to pharmaceutical innovation, regulatory affairs, scientific communication, and public policy amid evolving federal priorities and emerging technologies.

More on Marylandian

• Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
• ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
• New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
• MapleLMS Awarded GMP Certification for Compliance Training
• Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center

https://pharm-science.com/

About Ivyctory Solutions

Ivyctory Solutions is a market research and strategic advisory firm specializing in biomedical innovation, life sciences, regulatory affairs, and public policy. The firm provides evidence-based analysis, market intelligence, and strategic insights to support decision-making, evaluate emerging technologies, and navigate evolving scientific and regulatory environments.

Website: https://www.ivyctory.com